NCT00979368View on ClinicalTrials.gov

Safety Study of BMS-816336 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Diabetes Mellitus, Non-Insulin-DependentDyslipidemia
Interventions
DRUG

BMS-816336

Suspension, Oral, 15 mg Active, Once on Day 1 only, 4 days

DRUG

BMS-816336

Suspension, Oral, 60 mg Active, Once on Day 1 only, 4 days

DRUG

BMS-816336

Suspension, Oral, 180 mg Active, Once on Day 1 only, 4 days

DRUG

BMS-816336

Suspension, Oral, 450 mg Active, Once on Day 1 only, 4 days

DRUG

BMS-816336

Suspension, Oral, 900 mg Active, Once on Day 1 only, 4 days

DRUG

Placebo

Suspension, Oral, 0 mg, Once on Day 1 only, 4 days

Trial Locations (1)

3004

Local Institution, Melbourne

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY